Our client, a leading biotech innovator committed to developing revolutionary personalized therapies for dementia and Alzheimer’s disease patients, relies heavily on positive outcomes from its clinical trials. Yet, identifying appropriate patients with the right gene mutation for these trials can be a challenge.
When trial sites failed to identify enough patients for a phase 3 clinical trial targeting a rare genetic subtype of Frontotemporal Dementia (FTD), the sponsor partnered with InformedDNA to develop an institutional review board (IRB)-approved screening study for its direct-to-patient selection efforts.
InformedDNA’s genomics experts assisted in study design; triaged, counseled and tested patients; and streamlined and simplified processes that are often challenging for clinicians and researchers. Along the way, building trust also proved to be a game-changer for patient engagement.
InformedDNA is the largest full-service applied genomics solutions company in the U.S., with a suite of offerings for sponsors and CROs optimized to support clinical trials, natural history studies, and clinical research programs. Our services are designed to reduce time to enrollment, increase screening efficiencies, improve patient retention, mitigate sponsor risk, and reduce clinical trial costs.